Dailin Rong1,2, Yize Mao1, Qiuxia Yang1,2, Shuhang Xu3, Qianqian Zhao1,2, Rong Zhang4,5. 1. State Key Laboratory of Oncology in Southern China, Guangzhou, 510060, People's Republic of China. 2. Department of Radiology, Sun Yat-Sen University Cancer Center, No. 651 Dongfeng Road East, Guangzhou, 510060, People's Republic of China. 3. Department of Ultrasound, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510630, Guangdong Province, People's Republic of China. 4. State Key Laboratory of Oncology in Southern China, Guangzhou, 510060, People's Republic of China. zhangr@sysucc.org.cn. 5. Department of Radiology, Sun Yat-Sen University Cancer Center, No. 651 Dongfeng Road East, Guangzhou, 510060, People's Republic of China. zhangr@sysucc.org.cn.
Abstract
OBJECTIVES: To explore the relationship between osteosclerotic changes and chemotherapy response in non-small-cell lung cancer (NSCLC) patients with bone metastases (BM). METHODS: Fifty-two NSCLC patients with BM were enrolled from 1 January 2010-31 June 2015 and divided into two groups based on their CT features: an osteosclerotic change (OC) group and a no-osteosclerotic change (NOC) group. The disease control rate (DCR) was evaluated, and progression-free survival (PFS) was analysed using Kaplan-Meier curves. Univariate and multivariate Cox regression analyses were performed to analyse the factors that could affect PFS. RESULTS: Osteosclerotic changes were observed in 35/52 patients. The median interval when osteosclerotic changes occurred was 2 months (range 1-3 months) after chemotherapy. The OC group had a significantly higher 3-month DCR than the NOC group (p < 0.001). The OC group had a higher 1-year PFS rate than the NOC group (1-year PFS: 74.9% vs. 30.2%, p < 0.001). Univariate Cox regression analysis indicated that pathological subtype (HR = 4.419; 95% CI = 1.635-11.941, p = 0.003) and osteosclerotic changes (HR = 0.199; 95% CI = 0.083-0.477, p < 0.001) were significant predictors of PFS. CONCLUSION: Early osteosclerotic changes predict chemotherapy response in NSCLC patients with BM. KEY POINTS: • Osteosclerotic changes were prevalent CT features after chemotherapy in NSCLC patients. • Osteosclerotic changes were positively related to increased 3-month DCR. • Osteosclerotic changes were positively related to increased 1-year PFS rate.
OBJECTIVES: To explore the relationship between osteosclerotic changes and chemotherapy response in non-small-cell lung cancer (NSCLC) patients with bone metastases (BM). METHODS: Fifty-two NSCLCpatients with BM were enrolled from 1 January 2010-31 June 2015 and divided into two groups based on their CT features: an osteosclerotic change (OC) group and a no-osteosclerotic change (NOC) group. The disease control rate (DCR) was evaluated, and progression-free survival (PFS) was analysed using Kaplan-Meier curves. Univariate and multivariate Cox regression analyses were performed to analyse the factors that could affect PFS. RESULTS:Osteosclerotic changes were observed in 35/52 patients. The median interval when osteosclerotic changes occurred was 2 months (range 1-3 months) after chemotherapy. The OC group had a significantly higher 3-month DCR than the NOC group (p < 0.001). The OC group had a higher 1-year PFS rate than the NOC group (1-year PFS: 74.9% vs. 30.2%, p < 0.001). Univariate Cox regression analysis indicated that pathological subtype (HR = 4.419; 95% CI = 1.635-11.941, p = 0.003) and osteosclerotic changes (HR = 0.199; 95% CI = 0.083-0.477, p < 0.001) were significant predictors of PFS. CONCLUSION: Early osteosclerotic changes predict chemotherapy response in NSCLCpatients with BM. KEY POINTS: • Osteosclerotic changes were prevalent CT features after chemotherapy in NSCLCpatients. • Osteosclerotic changes were positively related to increased 3-month DCR. • Osteosclerotic changes were positively related to increased 1-year PFS rate.
Authors: David S Ettinger; Wallace Akerley; Hossein Borghaei; Andrew C Chang; Richard T Cheney; Lucian R Chirieac; Thomas A D'Amico; Todd L Demmy; Ramaswamy Govindan; Frederic W Grannis; Stefan C Grant; Leora Horn; Thierry M Jahan; Ritsuko Komaki; Feng-Ming Spring Kong; Mark G Kris; Lee M Krug; Rudy P Lackner; Inga T Lennes; Billy W Loo; Renato Martins; Gregory A Otterson; Jyoti D Patel; Mary C Pinder-Schenck; Katherine M Pisters; Karen Reckamp; Gregory J Riely; Eric Rohren; Theresa A Shapiro; Scott J Swanson; Kurt Tauer; Douglas E Wood; Stephen C Yang; Kristina Gregory; Miranda Hughes Journal: J Natl Compr Canc Netw Date: 2013-06-01 Impact factor: 11.908
Authors: Tsuyoshi Hamaoka; John E Madewell; Donald A Podoloff; Gabriel N Hortobagyi; Naoto T Ueno Journal: J Clin Oncol Date: 2004-07-15 Impact factor: 44.544
Authors: Robert Foerster; Christian Eisele; Thomas Bruckner; Tilman Bostel; Ingmar Schlampp; Robert Wolf; Juergen Debus; Harald Rief Journal: Radiat Oncol Date: 2015-03-07 Impact factor: 3.481
Authors: C C Quattrocchi; S Piciucchi; M Sammarra; D Santini; B Vincenzi; G Tonini; R F Grasso; B B Zobel Journal: Radiol Med Date: 2007-10-21 Impact factor: 6.313
Authors: Nan Sethakorn; Erika Heninger; Cristina Sánchez-de-Diego; Adeline B Ding; Ravi Chandra Yada; Sheena C Kerr; David Kosoff; David J Beebe; Joshua M Lang Journal: Cancers (Basel) Date: 2022-02-01 Impact factor: 6.639